Moreover, in line with the robust inhibitory effects observed after silencing PRPF8, this core component of the major spliceosome has already been associated to malignancy in prostate cancer [61], hepatocarcinoma [62, 63] and breast cancer [64]. Here, PRPF8 is linked to breast cancer.